Browsing by Author "González Muñoz, Pablo Alberto"
Now showing 1 - 20 of 21
Results Per Page
Sort Options
- ItemAsymptomatic Herpes Simplex Virus Type 1 Infection Causes an Earlier Onset and More Severe Experimental Autoimmune Encephalomyelitis(2021) Duarte Peñaloza, Luisa Fernanda; Altamirano Lagos, María J.; Tabares Guevara, Jorge H.; Opazo, María Cecilia; Díaz, Máximo; Navarrete, Romina; Muza, Catalina; Vallejos Galvez, Omar Patricio; Riedel Soria, Claudia; Bueno Ramírez, Susan; Kalergis Parra, Alexis Mikes; González Muñoz, Pablo AlbertoMultiple sclerosis (MS) is an increasingly prevalent progressive autoimmune and debilitating chronic disease that involves the detrimental recognition of central nervous system (CNS) antigens by the immune system. Although significant progress has been made in the last decades on the biology of MS and the identification of novel therapies to treat its symptoms, the etiology of this disease remains unknown. However, recent studies have suggested that viral infections may contribute to disease onset. Interestingly, a potential association between herpes simplex virus type 1 (HSV-1) infection and MS has been reported, yet a direct relationship among both has not been conclusively demonstrated. Experimental autoimmune encephalomyelitis (EAE) recapitulates several aspects of MS in humans and is widely used to study this disease. Here, we evaluated the effect of asymptomatic brain infection by HSV-1 on the onset and severity of EAE in C57BL/6 mice. We also evaluated the effect of infection with an HSV-1-mutant that is attenuated in neurovirulence and does not cause encephalitis. Importantly, we observed more severe EAE in mice previously infected either, with the wild-type (WT) or the mutant HSV-1, as compared to uninfected control mice. Also, earlier EAE onset was seen after WT virus inoculation. These findings support the notion that a previous exposure to HSV-1 can accelerate and enhance EAE, which suggests a potential contribution of asymptomatic HSV-1 to the onset and severity of MS.
- ItemDifferential Severe Acute Respiratory Syndrome Coronavirus 2-Specific Humoral Response in Inactivated Virus-Vaccinated, Convalescent, and Breakthrough-Infected Subjects(OXFORD UNIV PRESS INC, 2023) Duarte Peñaloza, Luisa Fernanda; Vazquez Hernandez Yaneisi; Diethelm Varela, Benjamin Manuel; Pavez, Valentina; Berrios-Rojas, Roslye; Riedel, Claudia A.; Mendez, Constanza; White, Jessica A.; Kalergis Parra, Alexis Mikes; Bueno Ramírez, Susan Marcela; González Muñoz, Pablo AlbertoBackground. We sought to identify potential antigens for discerning between humoral responses elicited after vaccination with CoronaVac (a severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2] inactivated vaccine), natural infection, or breakthrough infection., Methods. Serum samples obtained from volunteers immunized with CoronaVac (2 and 3 doses), breakthrough case patients, and from convalescent individuals were analyzed to determine the immunoglobulin (Ig) G responses against 3 structural and 8 nonstructural SARS-CoV-2 antigens., Results. Immunization with CoronaVac induced higher levels of antibodies against the viral membrane (M) protein compared with convalescent subjects both after primary vaccination and after a booster dose. Individuals receiving a booster dose displayed equivalent levels of IgG antibodies against the nucleocapsid (N) protein, similar to convalescent subjects. Breakthrough case patients produced the highest antibody levels against the N and M proteins. Antibodies against nonstructural viral proteins were present in >50% of the convalescent subjects., Conclusions. Vaccinated individuals elicited a different humoral response compared to convalescent subjects. The analysis of particular SARS-CoV-2 antigens could be used as biomarkers for determining infection in subjects previously vaccinated with CoronaVac.
- ItemEnhanced specialized transduction using recombineering in mycobacterium tuberculosis(2014) Tufariello, J. M.; González Muñoz, Pablo Alberto
- ItemFormulación inmunogénica que confiere protección contra la infección o patología causada por el virus respiratorio sincicial (VRS) que comprende una cepa recombinante atenuada de mycobacterium; y uso de la formulación inmunogénica para preparar una vacuna para prevenir, tratar o atenuar infecciones del VRS (Austria, concesión n° EP2207567)Kalergis Parra, Alexis Mikes; González Muñoz, Pablo Alberto; Bueno Ramírez, Susan
- ItemFormulación inmunogénica que confiere protección contra la infección o patología causada por el virus respiratorio sincicial (VRS) que comprende una cepa recombinante atenuada de mycobacterium; y uso de la formulación inmunogénica para preparar una vacuna para prevenir, tratar o atenuar infecciones del VRS (China, concesión n° ZL 200880114324.0)Kalergis Parra, Alexis Mikes; González Muñoz, Pablo Alberto; Bueno Ramírez, Susan
- ItemFormulación inmunogenica que confiere protección contra la infección o patología causada por el virus respiratorio sincicial (VRS) que comprende una cepa recombinante atenuada de mycobacterium; y uso de la formulación inmunogenica para preparar una vacuna para prevenir, tratar o atenuar infecciones del VRS (Estonia, concesión n° E010108)Kalergis Parra, Alexis Mikes; González Muñoz, Pablo Alberto; Bueno Ramírez, Susan
- ItemFormulación inmunogénica que confiere protección contra la infección o patología causada por el virus respiratorio sincicial (VRS) que comprende una cepa recombinante atenuada de mycobacterium; y uso de la formulación inmunogénica para preparar una vacuna para prevenir, tratar o atenuar infecciones del VRS (Letonia, concesión n° EP2207567)Kalergis Parra, Alexis Mikes; González Muñoz, Pablo Alberto; Bueno Ramírez, Susan
- ItemFormulación inmunogénica que confiere protección contra la infección o patología causada por el virus respiratorio sincicial (VRS) que comprende una cepa recombinante atenuada de mycobacterium; y uso de la formulación inmunogénica para preparar una vacuna para prevenir, tratar o atenuar infecciones del VRS (Lituania, concesión n° EP2207567)Kalergis Parra, Alexis Mikes; González Muñoz, Pablo Alberto; Bueno Ramírez, Susan
- ItemFormulación inmunogénica que contiene BCG vivas recombinantes que expresan antígenos de Metapneumovirus (hMPV), en una suspensión que se prepara a partir de un liofilizado sin la necesidad de adyuvante, apta para su uso farmacéutico (Reino Unido, concesión n° 3054013)Kalergis Parra, Alexis Mikes; Bueno Ramírez, Susan; González Muñoz, Pablo Alberto
- ItemHeme Oxygenase-1 Expression in Dendritic Cells Contributes to Protective Immunity against Herpes Simplex Virus Skin Infection(MDPI, 2023) Tognarelli Torres, Eduardo Ignacio; Duarte Peñaloza, Luisa Fernanda; Farías León, Mónica Andrea; Cancino Prado, Felipe Andrés; Corrales Bonilla, Nicolas; Ibañez Irribarra, Francisco Javier; Riedel Soria, Claudia; Bueno Ramírez, Susan; Kalergis Parra,Alexis Mikes; González Muñoz, Pablo AlbertoHerpes simplex virus type 1 (HSV-1) and type 2 (HSV-2) infections are highly prevalent in the human population and produce mild to life-threatening diseases. These viruses interfere with the function and viability of dendritic cells (DCs), which are professional antigen-presenting cells that initiate and regulate the host's antiviral immune responses. Heme oxygenase-1 (HO-1) is an inducible host enzyme with reported antiviral activity against HSVs in epithelial cells and neurons. Here, we sought to assess whether HO-1 modulates the function and viability of DCs upon infection with HSV-1 or HSV-2. We found that the stimulation of HO-1 expression in HSV-inoculated DCs significantly recovered the viability of these cells and hampered viral egress. Furthermore, HSV-infected DCs stimulated to express HO-1 promoted the expression of anti-inflammatory molecules, such as PDL-1 and IL-10, and the activation of virus-specific CD4(+) T cells with regulatory (Treg), Th17 and Treg/Th17 phenotypes. Moreover, HSV-infected DCs stimulated to express HO-1 and then transferred into mice, promoted the activation of virus-specific T cells and improved the outcome of HSV-1 skin infection. These findings suggest that stimulation of HO-1 expression in DCs limits the deleterious effects of HSVs over these cells and induces a favorable virus-specific immune response in the skin against HSV-1.
- ItemHerpes simplex virus 2 infection: molecular association with HIV and novel microbicides to prevent disease.(2015) Suazo, P. A.; Tognarelli Torres, Eduardo Ignacio; Kalergis Parra, Alexis Mikes; González Muñoz, Pablo Alberto
- ItemHost immunity during RSV pathogenesis(2008) Bueno Ramírez, Susan; González Muñoz, Pablo Alberto; Pacheco, Rodrigo; Leiva Llantén, Eduardo David; Cautivo Reyes, Kelly Margarita; Tobar Durán, Hugo Eduardo; Mora, Jorge E.; Prado, Carolina E.; Zuniga, Juan P.; Jimenez, Jorge; Riedel, Claudia A.; Kalergis Parra, Alexis Mikes
- ItemHuman metapneumovirus keeps dendritic cells from priming antigen-specific naive T cells(2013) Céspedes Donoso, Pablo Francisco; González Muñoz, Pablo Alberto; Kalergis Parra, Alexis Mikes
- ItemHuman Respiratory Syncytial Virus: Infection and Pathology(2016) Bohmwald Prieto, Karen; Espinoza Véliz, Janyra Alejandra; Rey Jurado, Emma; Gómez Johnson, Roberto Sebastian; González Muñoz, Pablo Alberto; Bueno Ramírez, Susan; Riedel, Claudia A.; Kalergis Parra, Alexis MikesThe human respiratory syncytial virus (hRSV) is by far the major cause of acute lower respiratory tract infections (ALRTIs) worldwide in infants and children younger than 2 years. The overwhelming number of hospitalizations due to hRSV-induced ALRTI each year is due, at least in part, to the lack of licensed vaccines against this virus. Thus, hRSV infection is considered a major public health problem and economic burden in most countries. The lung pathology developed in hRSV-infected individuals is characterized by an exacerbated proinflammatory and unbalanced Th2-type immune response. In addition to the adverse effects in airway tissues, hRSV infection can also cause neurologic manifestations in the host, such as seizures and encephalopathy. Although the origins of these extrapulmonary symptoms remain unclear, studies with patients suffering from neurological alterations suggest an involvement of the inflammatory response against hRSV. Furthermore, hRSV has evolved numerous mechanisms to modulate and evade the immune response in the host. Several studies have focused on elucidating the interactions between hRSV virulence factors and the host immune system, to rationally design new vaccines and therapies against this virus. Here, we discuss about the infection, pathology, and immune response triggered by hRSV in the host.
- ItemIs there a role for herpes simplex virus type 1 in multiple sclerosis?(ELSEVIER, 2023) Duarte, Luisa F.; Gatica, Sebastian; Castillo, Almendra; Kalergis Parra, Alexis Mikes; Bueno Ramírez, Susan Marcela; Riedel, Claudia A.; González Muñoz, Pablo AlbertoNumerous studies relate the onset and severity of multiple sclerosis (MS) with viral infections. Herpes simplex virus type 1 (HSV-1), which is neurotropic and highly prevalent in the brain of healthy in-dividuals, has been proposed to relate to MS. Here, we review and discuss the reported connections between HSV-1 and MS.(c) 2022 The Author(s). Published by Elsevier Masson SAS on behalf of Institut Pasteur. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
- ItemLung pathology due to hRSV infection impairs blood–brain barrier permeability enabling astrocyte infection and a long-lasting inflammation in the CNS(2021) Bohmwald Prieto, Karen; Soto Ramírez, Jorge Andrés; Andrade Parra, Catalina Andrea; Fernández Fierro, Ayleen Lorena; Espinoza Véliz, Janyra Alejandra; Rios Raggio, Mariana; Eugenin, E. A.; González Muñoz, Pablo Alberto; Opazo, M. C.; Kalergis Parra, Alexis Mikes
- ItemNovel therapies and vaccines against the human respiratory syncytial virus(2015) Rivera, C.; Gómez Johnson, Roberto Sebastian; Díaz Montero, Rodrigo Aquiles; Céspedes, P.; Espinoza Véliz, Janyra Alejandra; González Muñoz, Pablo Alberto; Riedel, C.; Bueno Ramírez, Susan; Kalergis Parra, Alexis Mikes
- ItemPharmacological Induction of Heme Oxygenase-1 Impairs Nuclear Accumulation of Herpes Simplex Virus Capsids upon Infection(2017) Ibáñez, Francisco J.; Farías, Mónica A.; Retamal Díaz, Angello Ricardo; Espinoza Véliz, Janyra Alejandra; Kalergis Parra, Alexis Mikes; González Muñoz, Pablo Alberto
- ItemSpecialized transduction designed for precise high-throughput unmarked deletions in Mycobacterium tuberculosis.(2014) Jain, P.; González Muñoz, Pablo Alberto
- ItemTackling cutaneous herpes simplex virus disease with topical immunomodulators—a call to action(2025) Duarte, Luisa F.; Carbone Schellman, Javier; Bueno Ramírez, Susan Marcela; Kalergis Parra, Alexis Mikes; Riedel, Claudia A.; González Muñoz, Pablo Alberto